Medicare’s imminent coverage of obesity drugs opens a major new market for GLP-1 manufacturers while posing fiscal challenges for the U.S. health program
Executive summary: Medicare will start covering obesity drugs such as GLP-1 agonists for eligible beneficiaries beginning July 1, 2026, marking the first time the program includes weight-loss medications. This expands access to effective obesity treatment for millions of seniors, potentially improving health outcomes while increasing Medicare outpatient drug expenditures and creating a new revenue stream for drug manufacturers. Centers for Medicare & Medicaid Services (CMS), pharmaceutical companies Eli Lilly and Novo Lilly, and approximately 65 million Medicare beneficiaries. CMS will conduct outreach to inform beneficiaries, monitor utilization and costs, and may adjust coverage criteria based on early utilization data.
On June 28, 2026, CNBC reported that Medicare’s upcoming coverage of obesity drugs will begin July 1, yet many seniors remain unaware due to limited government and manufacturer outreach. The decision follows years of debate over the cost-effectiveness of GLP-1 therapies and reflects a broader shift toward covering preventive treatments under Medicare. While the move could boost sales for Eli Lilly and Novo Nordisk, it also raises questions about the program’s budgetary impact and the need for safeguards against overuse.
Connected developments
- Historical Medicare coverage and obesity drug developments
- We read the Social Security and Medicare trustees reports. If you’re not worried, you should be.
- Social Security’s woes are well known, but Medicare is also facing a fiscal crisis — in just 7 years
- ‘This would be a one-time event’: How can I take extra money from my 401(k) without triggering higher Medicare premiums?
Open the full case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped